4 results on '"Ramos da Silva, Jamile"'
Search Results
2. Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice.
- Author
-
Ramos da Silva, Jamile, Bitencourt Rodrigues, Karine, Formoso Pelegrin, Guilherme, Silva Sales, Natiely, Muramatsu, Hiromi, de Oliveira Silva, Mariângela, Porchia, Bruna F. M. M., Moreno, Ana Carolina Ramos, Aps, Luana Raposo M. M., Venceslau-Carvalho, Aléxia Adrianne, Tombácz, István, Fotoran, Wesley Luzetti, Karikó, Katalin, Lin, Paulo J. C., Tam, Ying K., de Oliveira Diniz, Mariana, Pardi, Norbert, and de Souza Ferreira, Luís Carlos
- Subjects
HUMAN herpesvirus 1 ,VACCINE trials ,HUMAN papillomavirus ,TRANSMISSIBLE tumors ,NANOMEDICINE ,COVID-19 ,CHIMERIC proteins - Abstract
As mRNA vaccines have proved to be very successful in battling the coronavirus disease 2019 (COVID-19) pandemic, this new modality has attracted widespread interest for the development of potent vaccines against other infectious diseases and cancer. Cervical cancer caused by persistent human papillomavirus (HPV) infection is a major cause of cancer-related deaths in women, and the development of safe and effective therapeutic strategies is urgently needed. In the present study, we compared the performance of three different mRNA vaccine modalities to target tumors associated with HPV-16 infection in mice. We generated lipid nanoparticle (LNP)–encapsulated self-amplifying mRNA as well as unmodified and nucleoside-modified non-replicating mRNA vaccines encoding a chimeric protein derived from the fusion of the HPV-16 E7 oncoprotein and the herpes simplex virus type 1 glycoprotein D (gDE7). We demonstrated that single low-dose immunizations with any of the three gDE7 mRNA vaccines induced activation of E7-specific CD8
+ T cells, generated memory T cell responses capable of preventing tumor relapses, and eradicated subcutaneous tumors at different growth stages. In addition, the gDE7 mRNA-LNP vaccines induced potent tumor protection in two different orthotopic mouse tumor models after administration of a single vaccine dose. Last, comparative studies demonstrated that all three gDE7 mRNA-LNP vaccines proved to be superior to gDE7 DNA and gDE7 recombinant protein vaccines. Collectively, we demonstrated the immunogenicity and therapeutic efficacy of three different mRNA vaccines in extensive comparative experiments. Our data support further evaluation of these mRNA vaccines in clinical trials. Comparing mRNA vaccines head-to-head: mRNA vaccines can be delivered through multiple platforms. Here, Ramos da Silva and colleagues compared three different mRNA platforms as a therapeutic vaccine for human papillomavirus–associated cancers. The three vaccines tested were an unmodified non-replicating mRNA vaccine, a nucleoside-modified non-replicating mRNA vaccine, and a self-amplifying mRNA vaccine. All three vaccines encoded the same antigen, a fusion protein of the HPV-16 E7 oncoprotein and the herpes simplex virus type 1 glycoprotein D, so differences between the vaccines' efficacy were due to the platform. The authors found that a single dose of self-amplifying or unmodified non-replicating mRNA vaccines, both encapsulated in lipid nanoparticles, led to robust control of tumor burden in two orthotopic murine models. Further, all three vaccines outperformed a protein vaccine and an electroporated DNA vaccine containing or encoding the same antigen. These results highlight the translational potential of mRNA cancer vaccines. —CM [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
3. Interleukin-6 and indoleamine-2,3-dioxygenase as potential adjuvant targets for Papillomavirus-related tumors immunotherapy.
- Author
-
Liberato Pagni, Roberta, da Cruz Souza, Patrícia, Pegoraro, Rafael, Maldonado Porchia, Bruna Felício Milazzotto, Ramos da Silva, Jamile, de Melo Moraes Aps, Luana Raposo, de Oliveira Silva, Mariângela, Bitencourt Rodrigues, Karine, Silva Sales, Natiely, de Souza Ferreira, Luís Carlos, and Ramos Moreno, Ana Carolina
- Subjects
REGULATORY T cells ,MYELOID-derived suppressor cells ,BACTERIAL vaccines ,INTERLEUKIN-6 ,IMMUNOTHERAPY ,DNA vaccines - Abstract
High-risk Human papillomavirus (HPV) infections represent an important public health issue. Nearly all cervical malignancies are associated with HPV, and a range of other female and male cancers, such as anogenital and oropharyngeal. Aiming to treat HPV-related tumors, our group developed vaccines based on the genetic fusion of the HSV-1 glycoprotein D (gD) with the HPV-16 E7 oncoprotein (gDE7 vaccines). Despite the promising antitumor results reached by gDE7 vaccines in mice, combined therapies may increase the therapeutic effects by improving antitumor responses and halting immune suppressive mechanisms elicited by tumor cells. Considering cancer immunosuppressive mechanisms, indoleamine-2,3-dioxygenase (IDO) enzyme and interleukin-6 (IL-6) stand out in HPV-related tumors. Since IL-6 sustained the constitutive IDO expression, here we evaluated the therapeutic outcomes achieved by the combination of active immunotherapy based on a gDE7 protein-based vaccine with adjuvant treatments involving blocking IDO, either by use of IDO inhibitors or IL-6 knockout mice. C57BL/6 wild-type (WT) and transgenic IL-6-/- mice were engrafted with HPV16-E6/E7-expressing TC-1 cells and treated with 1-methyltryptophan isoforms (D-1MT and DL-1MT), capable to inhibit IDO. In vitro, the 1MT isoforms reduced IL-6 gene expression and IL-6 secretion in TC-1 cells. In vivo, the multi-targeted treatment improved the antitumor efficacy of the gDE7- based protein vaccine. Although the gDE7 immunization achieves partial tumor mass control in combination with D-1MT or DL-1MT in WT mice or when administered in IL-6-/- mice, the combination of gDE7 and 1MT in IL-6-/- mice further enhanced the antitumor effects, reaching total tumor rejection. The outcome of the combined therapy was associated with an increased frequency of activated dendritic cells and decreased frequencies of intratumoral polymorphonuclear myeloid-derived suppressor cells and T regulatory cells. In conclusion, the present study demonstrated that IL-6 and IDO negatively contribute to the activation of immune cells, particularly dendritic cells, reducing gDE7 vaccine-induced protective immune responses and, therefore, opening perspectives for the use of combined strategies based on inhibition of IL-6 and IDO as immunometabolic adjuvants for immunotherapies against HPVrelated tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Active immunization combined with cisplatin confers enhanced therapeutic protection and prevents relapses of HPV-induced tumors at different anatomical sites.
- Author
-
Milazzotto Maldonado Porchia, Bruna Felício, de Melo Moraes Aps, Luana Raposo, Ramos Moreno, Ana Carolina, Ramos da Silva, Jamile, de Oliveira Silva, Mariângela, Silva Sales, Natiely, dos Santos Alves, Rubens Prince, Reily Rocha, Clarissa Ribeiro, Molina Silva, Matheus, Bitencourt Rodrigues, Karine, Borges Barros, Tácita, Liberato Pagni, Roberta, da Cruz Souza, Patrícia, de Oliveira Diniz, Mariana, and de Souza Ferreira, Luís Carlos
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.